Skip to main content
. 2020 May 16;21(10):3528. doi: 10.3390/ijms21103528
LA locally advanced
BC breast cancer
HR+ hormone receptor positive
pCR pathological complete response
NCT neoadjuvant chemotherapy
NET neoadjuvant endocrine therapy
ER estrogen receptors
PgR progesterone receptors
HER2- hormone epidermal growth factor 2 negative
TN triple negative
BCS breast conservative surgery
ObR objective response
PEPI preoperative endocrine prognostic index
DBs databases
CENTRAL Cochrane Central Register of Controlled Trials
MeSH Medical Subject Headings
ASCO American Society of Clinical Oncology
AACR American Association of Cancer Research
OS overall survival
OR odds ratio
CI confidence interval
DFS disease free survival
ORR overall response rate
EC epirubicin-cyclophosphamide
RFS relapse free survival
pATR phosphorylated ataxia-teleangectasia and Rad3-related protein
ATM phosphorylated ataxia-telangiectasia mutated
γ-H2AX phosphorylated H2A Histone Family Member X
CCCA complete cell cycle arrest
RCB residual cancer burden
eBC early breast cancer
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
AKT1 RAC-alpha serine/threonine-protein kinase
PTEN Phosphatase and tensin homolog
FGFR1 fibroblast grow factor receptor 1
TILs Tumor-infiltrating lymphocytes
PD-L1 Programmed death-ligand 1
PD-1 Programmed death-1
POAI peri-operative aromatase inhibitor
TTR time to recurrence
WoTs window of opportunity trials
CDK4/6 cyclin-dependent kinase 4 and 6